While previous studies primarily focused on the role of propofol in tumor-associated angiogenesis via modulation of VEGF secretion from cancer cells, our findings reveal that propofol acts directly on ECs in non-tumor pathological contexts, highlighting its broader pharmacological significance. This evidence concerns the gene VEGFA and neoplasm.